This report assesses the Shariah compliance of MRAL, a clinical-stage biotechnology company focused on oncology. Due to insufficient financial data availability, key ratios cannot be computed, leading to an overall UNDER_REVIEW status. Business activities in healthcare appear permissible, with no identified non-compliant revenues. Index inclusions remain unknown, and ESG factors show low risk with strong governance. Investors should await further disclosures for definitive compliance.